Gastrointestinal therapeutics Market Research Reports

"...... lyte disturbances, and malnutrition. During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the ......"

"...... eatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI. Market Analysis and Insights: Global ......"

"...... stry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations wer......"

"...... 24.7 million in 2020. Over the next five years the Anti-Peptic Ulcer Drugs market will register a 13.9% CAGR in terms of revenue, the global market size will reach US$ 12660 million by 2026. This report presents a comprehensive overvie......"

"...... the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendat......"

"...... y the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for A......"

"...... lion in 2020. Over the next five years the Gastroparesis Drugs market will register a 4.5% CAGR in terms of revenue, the global market size will reach US$ 6334.6 million by 2026. This report presents a comprehensive overview, market sh......"

"...... nant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%. North America is the la......"

"...... t by Type and by Application for the period 2016-2027. Segment by Type - Prokinetic Agents - Antiemetic Agents - Others Segment by Application - Diabetic Gastroparesis - Idiopathic Gast......"

"...... 1, from US$ 4041 million in 2020. Over the next five years the Irritable Bowel Syndrome (IBS) market will register a 15.6% CAGR in terms of revenue, the global market size will reach US$ 7206.6 million by 2026. This report presents a c......"